Connect with us
In 2024, Spanish pharma focused on stabilizing finances rather than expanding, with six major players seeing an 18% profit drop compared to 2023. While Faes Farma...
Spanish pharmaceutical stocks dropped 10% in November, led by Rovi's 17.5% plunge amid profit and turnover declines. Grifols also fell 16%, impacted by OPA cancellation and...
Rovi's EBITDA fell by 2% to €167.2 million, and operating income decreased 5% to €564.6 million from January to September 2024, largely due to reduced COVID...
Rovi shares fell 10.5%, contributing to a 1.9% decline in Spain's pharmaceutical sector. Almirall also dropped 1.2%, while PharmaMar and Grifols rose 22.4% and 1.4%, respectively....
Spanish pharmaceutical companies had mixed results: Almirall and Reig Jofre shares dropped by 4% and 2.5%, respectively, while Faes Farma and PharmaMar saw increases of around...
According to the results presented by the pharmaceutical giants to the National Securities Commission (CNMV), the revenues of these five companies also rose in the first...
PharmaMar's turnover rose 0.8% in H1 2024, reaching €80.8 million, with oncology sales down 3.2%. Royalty income increased by 16%, while non-recurring income slightly declined. R&D...
Grifols and PharmaMar significantly dropped Spanish pharmaceutical stocks, with declines of 49.1% and 22.5% respectively in the first half of 2024. Although other companies like Rovi...
Rovi has gained FDA approval for its drug Risvan to treat schizophrenia in adults. The approval led to a nearly 3% surge in Rovi's stock. Risvan,...
Of the Spanish pharma listed companies, PharmaMar has suffered the most significant drop in profits due to generic drug competition with its star drug. Rovi has...